1901-LB: Safety and Glycemic Outcomes Using the MiniMed 780G System with a Disposable All-in-One Sensor with Transmitter
GREGORY P. FORLENZA,SARAH A. MACLEISH,DOROTHY I. SHULMAN,BENJAMIN U. NWOSU,SIHAM ACCACHA,SATISH K. GARG,ANDERS L. CARLSON,KRISTIN N. CASTORINO,BRYNN E. MARKS,RAYHAN LAL,CATHERINE PIHOKER,JAMES THRASHER,LORI M. LAFFEL,BHUVANA SUNIL,BRUCE W. BODE,JENNIFER L. SHERR,LAYA EKHLASPOUR,JOHN H. REED,M. JENNIFER ABUZZAHAB,MEI MEI CHURCH,ZHENG DAI,HAOXI MA,JED SOLOMON,YURI TREMINIO,JOHN SHIN,ANDREW S. RHINEHART,JENNIFER MCVEAN,ROBERT A. VIGERSKY,FOR THE SUCCEED STUDY GROUP
DOI: https://doi.org/10.2337/db24-1901-lb
IF: 7.7
2024-06-14
Diabetes
Abstract:Objective: The present study assessed impact of the MiniMedTM 780G (MM780G) advanced hybrid closed-loop (AHCL) system on glycemic metrics and safety when used with the disposable all-in-one Simplera SyncTM sensor*. Methods: Youths (aged 7-17yrs) and adults (aged 18-80yrs) with T1D were enrolled in a single-arm study (24 U.S. sites) with a ~2-week run-in where HCL (Auto Basal only) or open-loop delivery was used. This was followed by a three-month study period with AHCL activated. Glycemic outcomes and insulin delivered during the last 6-7 weeks of the study, in which system settings were optimized at investigator’s discretion, were compared to those of the run-in. Impact of recommended optimal settings (ROS, 100 mg/dL glucose target [GT] with a 2hr active insulin time [AIT]), was explored. Results: All groups showed significantly increased TIR and TITR and significantly reduced TAR, compared to run-in (Table). Use of ROS further improved TIR, TITR and TAR, in part, due to >60% automated basal and bolus delivery. No episodes of device-related severe hypoglycemia or DKA occurred. Conclusion: Use of the MM780G with the Simplera SyncTM sensor was safe and demonstrated improved glycemic outcomes, compared with run-in, and compared to glycemic outcomes of the pivotal trials1,2. Similarly, a lower GT and shorter AIT were associated with a further increased TIR and reduced TAR and, here, an increased TITR. Disclosure G.P. Forlenza: Research Support; Abbott, Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; Insulet Corporation. Consultant; Insulet Corporation. Research Support; Medtronic. Advisory Panel; Medtronic. Research Support; Tandem Diabetes Care, Inc. Consultant; Tandem Diabetes Care, Inc. S.A. MacLeish: Speaker's Bureau; Insulet Corporation. Advisory Panel; Prevention Bio. D.I. Shulman: Advisory Panel; Medtronic. Research Support; Medtronic. S. Accacha: Speaker's Bureau; Azurity. S.K. Garg: Research Support; Eli Lilly and Company. Advisory Panel; Medtronic. Research Support; Medtronic. Advisory Panel; Novo Nordisk. Research Support; DarioHealth Corp., Dexcom, Inc., Diasome. Advisory Panel; Roche Diabetes Care. A.L. Carlson: Research Support; Medtronic, Insulet Corporation, Tandem Diabetes Care, Inc., Eli Lilly and Company, Sanofi. Other Relationship; Novo Nordisk. Advisory Panel; MannKind Corporation. Research Support; Dexcom, Inc. K.N. Castorino: Research Support; Abbott, Dexcom, Inc. Speaker's Bureau; Dexcom, Inc. Research Support; Lilly Diabetes, Medtronic, MannKind Corporation, Insulet Corporation. Consultant; Medscape. B.E. Marks: Research Support; Tandem Diabetes Care, Inc., Dexcom, Inc., Medtronic, Digostics. Advisory Panel; International Society for Pediatric and Adolescent Diabetes, American Diabetes Association, T1D Exchange. Board Member; Juvenile Diabetes Research Foundation (JDRF). R. Lal: Consultant; Abbott, Adaptyx Biosciences, Biolinq, Capillary Biomedical, Inc., Deep Valley Labs, Gluroo, PhysioLogic Devices, Portal Insulin, Tidepool. Advisory Panel; Lilly Diabetes. C. Pihoker: None. J. Thrasher: Advisory Panel; Medtronic. Board Member; Medtronic. Research Support; Medtronic. Speaker's Bureau; Medtronic. Research Support; Eli Lilly and Company, Novo Nordisk. Speaker's Bureau; Bayer Inc. L.M. Laffel: Consultant; Dexcom, Inc. Advisory Panel; Medscape, Medtronic, Vertex Pharmaceuticals Incorporated. Consultant; Novo Nordisk. Advisory Panel; Lilly Diabetes, Provention Bio, Inc., Sanofi-Aventis U.S., Janssen Pharmaceuticals, Inc., MannKind Corporation. B. Sunil: None. B.W. Bode: Research Support; Omnipod. Speaker's Bureau; Omnipod. Research Support; Medtronic. Advisory Panel; Medtronic. J.L. Sherr: Consultant; Medtronic. Advisory Panel; Medtronic, Insulet Corporation. Speaker's Bureau; Insulet Corporation. Advisory Panel; Vertex Pharmaceuticals Incorporated, MannKind Corporation, StartUp Health T1D Moonshot, Bigfoot Biomedical, Inc., Cecelia Health. Speaker's Bureau; Zealand Pharma A/S. L. Ekhlaspour: Advisory Panel; Medtronic. Consultant; Medtronic, Tandem Diabetes Care, Inc. Advisory Panel; Tandem Diabetes Care, Inc. Research Support; Medtronic, MannKind Corporation. Advisory Panel; Sequel. Other Relationship; National Institutes of Health. Research Support; Juvenile Diabetes Research Foundation (JDRF). Speaker's Bureau; Insulet Corporation. J.H. Reed: None. M. Abuzzahab: Research Support; Ascendis Pharma A/S. Consultant; Ascendis Pharma A/S. Research Support; Medtronic, MannKind Corporation, Rhythm Pharmaceuticals, Inc. Consultant; Rhythm Pharmaceuticals, Inc. Research Support; Novo Nordisk. M. Church: None. Z. Dai: Employee; Medtronic. H. Ma: None. J. Solomon: None. Y. Treminio: Employee; Medtronic. J. Shin: None. A.S. Rhinehart: Employee; Medtronic. Stock/Shareholder; Medtronic. J. McVean: Employee; Medtronic. R.A. Vigersky: Employee; Medtronic.
endocrinology & metabolism